

~~IAP9 Rec'd PCT/PTO 31 JAN 2006~~

## INFORMATION DISCLOSURE STATEMENT

Applicant	:	Jin, et al.
App. No	:	Unknown
Filed	:	Herewith
For	:	PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION
Examiner	:	Unknown
Art Unit	:	Unknown

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

Enclosed for filing in the above-identified application is a PTO/SB/08 Equivalent listing 18 references to be considered by the Examiner. Seventeen references are enclosed.

This Information Disclosure Statement is being filed upon the filing date of the application and no fee is required.

The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment, to Account No. 11-1410.

Respectfully submitted,

KNOBBE, MARTENS, OLSON & BEAR, LLP

Dated: Jan. 31, 2006

By: Che S. Chereskin

Che Swyden Chereskin, Ph.D.

Registration No. 41,466

Agent of Record

Customer No. 20,995

(949) 760-0404

INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Application No.	1AP9 Rec'd PCT/PTO 31 JAN 2006
	Filing Date	Herewith
	First Named Inventor	Jin, et al.
	Art Unit	Unknown
(Multiple sheets used when necessary)	Examiner	Unknown
SHEET 1 OF 2	Attorney Docket No.	TOYA145.001APC

## U.S. PATENT DOCUMENTS

Examiner Initials	Cite No.	Document Number Number - Kind Code (if known) Example: 1,234,567 B1	Publication Date MM-DD-YYYY	Name of Patentee or Applicant	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear
		2004/253314	12/16/04	Petereit, et al.	

## FOREIGN PATENT DOCUMENTS

Examiner Initials	Cite No.	Foreign Patent Document Country Code-Number-Kind Code Example: JP 1234567 A1	Publication Date MM-DD-YYYY	Name of Patentee or Applicant	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear	T <sup>1</sup>
		WO 96/15786	05/30/96	Glaxo Wellcome, Inc.		
		WO 98/00159	01/08/98	Oxigene, Inc.		
		WO 99/20285	04/29/99	Sanwa Kagaku Kenkyusho Co., Ltd.		Abstract
		WO 01/66083	09/13/01	Taisho Pharmaceutical Co., Ltd.		Abstract
		WO 01/89476	11/29/01	NPD LLC		
		WO 02/074100	09/26/02	Taisho Pharmaceutical Co., Ltd.		Abstract
		EP 0 379 147	07/25/90	Sterling Drug Inc.		
		EP 1 031 345	08/30/00	Sanwa Kagaku Kenkyusho Co., Ltd.		
		JP 10-236980	09/08/98	Hisamitsu Pharmaceutical Co., Inc.		Abstract
		JP 11-092402	04/06/99	Eisai Co., Ltd.		Abstract
		JP 11-322606	11/24/99	Kobayashi Seiyaku Kogyo KK		Abstract
		JP 2001-114696	04/24/01	Ohta Pharmaceutical Co., Ltd.		Abstract

## NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>1</sup>
		Leak, et al. "Pharmaceutical Development of Ondansetron Injection," <i>European Journal of Cancer &amp; Clinical Oncology</i> , Vol. 25, Suppl. 1, pp. 567-569, 1989.	
		Ll��cer, et al. "Adsorption-Desorption of Ondansetron on Latex Particles," <i>Drug Development and Industrial Pharmacy</i> , Vol. 26, No. 3, pp. 237-242, 2000.	
		Quercia, et al. "Stability of Granisetron Hydrochloride in an Extemporaneously Prepared Oral Liquid," <i>American Journal of Health-System Pharmacy</i> , Vol. 54, pp. 1404-1406, June 15, 1997.	

Examiner Signature	Date Considered
--------------------	-----------------

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

T<sup>1</sup> - Place a check mark in the area when an English language translation is attached. ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /C.R./

10/566829

PTO/SB/08 Equivalent

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Multiple sheets used when necessary)</i>	Application No.	10/566829
	Filing Date	Herewith
	First Named Inventor	Jin, et al.
	Art Unit	Unknown
	Examiner	Unknown
SHEET 2 OF 2	Attorney Docket No.	TOYA145.001APC

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>1</sup>
		Ruiz, et al. "Physical Characteristics of Polymer Complexes in Suspension Obtained from Cellulosic Latexes with Ondonsetron," <i>Journal of Materials Science: Materials in Medicine</i> , Vol. 15, pp. 659-664, 2004.	
		International Search Report	

2321326  
012406

Examiner Signature	/Craig Ricci/	Date Considered	06/03/2008
<p><b>*Examiner:</b> Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>			

T<sup>1</sup> - Place a check mark in this area when an English language translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /C.R./